相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Adcitmer(R), a new CD56-targeting monomethyl auristatin E-conjugated antibody, is a potential therapeutic approach in Merkel cell carcinoma
C. Esnault et al.
BRITISH JOURNAL OF DERMATOLOGY (2022)
Prevalence of delta-like protein 3 expression in Merkel cell carcinoma
Jamie Rand et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2021)
ICOS Is Widely Expressed in Cutaneous T-Cell Lymphoma and Its Targeting Promotes Potent Killing of Malignant Cells
Florent Amatore et al.
BLOOD (2021)
A Novel Antibody Drug Conjugate (ADC) Targeting Cell Surface Heat Shock Protein 70 (csHSP70) Is Active Against Pre-Clinical Models of Peripheral T-Cell Lymphoma (PTCL)
Rajan Kumar Choudhary et al.
BLOOD (2021)
Innovative Bioconjugation Technology for Antibody-Drug Conjugates: Proof of Concept in a CD30-Positive Lymphoma Mouse Model
Ludovic Juen et al.
BIOCONJUGATE CHEMISTRY (2021)
An Insight into FDA Approved Antibody-Drug Conjugates for Cancer Therapy
Juliana T. W. Tong et al.
MOLECULES (2021)
Longer term outcomes with single-agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13-month follow-up from the pivotal DREAMM-2 study
Sagar Lonial et al.
CANCER (2021)
Potential drugs used in the antibody-drug conjugate (ADC) architecture for cancer therapy
Sajad Yaghoubi et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2020)
Phase I study of the anti-endothelin B receptor antibody-drug conjugate DEDN6526A in patients with metastatic or unresectable cutaneous, mucosal, or uveal melanoma
Shahneen Sandhu et al.
INVESTIGATIONAL NEW DRUGS (2020)
Alteration of Physicochemical Properties for Antibody-Drug Conjugates and Their Impact on Stability
Jakob W. Buecheler et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2020)
Probody Therapeutics: An Emerging Class of Therapies Designed to Enhance On-Target Effects with Reduced Off-Tumor Toxicity for Use in Immuno-Oncology
Karen A. Autio et al.
CLINICAL CANCER RESEARCH (2020)
Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Laurie H. Sehn et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
ADCs, as Novel Revolutionary Weapons for Providing a Step Forward Targeted Therapy of Malignancies
Nooshafarin Amani et al.
CURRENT DRUG DELIVERY (2020)
European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 2. Treatment
Alexander J. Stratigos et al.
EUROPEAN JOURNAL OF CANCER (2020)
Phase Ib study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer
David M. O'Malley et al.
GYNECOLOGIC ONCOLOGY (2020)
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer
Shanu Modi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Systemic Therapy for Melanoma: ASCO Guideline
Rahul Seth et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
The neonatal Fc receptor in cancer FcRn in cancer
Diana Cadena Castaneda et al.
CANCER MEDICINE (2020)
Avelumab in patients with previously treated metastatic Merkel cell carcinoma: long-term data and biomarker analyses from the single-arm phase 2 JAVELIN Merkel 200 trial
Sandra P. D'Angelo et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Advances in Antibody-Drug Conjugate Design: Current Clinical Landscape and Future Innovations
Laurence Gauzy-Lazo et al.
SLAS DISCOVERY (2020)
Delta-like Protein 3 Expression and Targeting in Merkel Cell Carcinoma
Hao Xie et al.
ONCOLOGIST (2020)
Antibody-Drug Conjugates: The Last Decade
Nicolas Joubert et al.
PHARMACEUTICALS (2020)
The tumor targeting performance of anti-CD166 Probody drug conjugate CX-2009 and its parental derivatives as monitored by 89Zr-immuno-PET in xenograft bearing mice
Marion Chomet et al.
THERANOSTICS (2020)
Antibody Conjugates-Recent Advances and Future Innovations
Donmienne Leung et al.
ANTIBODIES (2020)
A Phase I Study to Assess the Safety and Pharmacokinetics of Single-agent Lorvotuzumab Mertansine (IMGN901) in Patients with Relapsed and/or Refractory CD-56-positive Multiple Myeloma
Sikander Ailawadhi et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2019)
Durable Tumor Regression and Overall Survival in Patients With Advanced Merkel Cell Carcinoma Receiving Pembrolizumab as First-Line Therapy
Paul Nghiem et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1-2 trial
Johann S. de Bono et al.
LANCET ONCOLOGY (2019)
Development of Effective Therapeutics Targeting HER3 for Cancer Treatment
Xiaolong Liu et al.
BIOLOGICAL PROCEDURES ONLINE (2019)
Targeting Topoisomerase I in the Era of Precision Medicine
Anish Thomas et al.
CLINICAL CANCER RESEARCH (2019)
A Novel HER3-Targeting Antibody-Drug Conjugate, U3-1402, Exhibits Potent Therapeutic Efficacy through the Delivery of Cytotoxic Payload by Efficient Internalization
Yuuri Hashimoto et al.
CLINICAL CANCER RESEARCH (2019)
Efficacy and Safety of Rovalpituzumab Tesirine in Third-Line and Beyond Patients with DLL3-Expressing, Relapsed/Refractory Small-Cell Lung Cancer: Results From the Phase II TRINITY Study
Daniel Morgensztern et al.
CLINICAL CANCER RESEARCH (2019)
Variable loss of CD30 expression by immunohistochemistry in recurrent cutaneous CD30+lymphoid neoplasms treated with brentuximab vedotin
Amrita Goyal et al.
JOURNAL OF CUTANEOUS PATHOLOGY (2019)
Antibody-drug conjugates for cancer
Cindy H. Chau et al.
LANCET (2019)
Cemiplimab-rwlc as first and only treatment for advanced cutaneous squamous cell carcinoma
Saqib R. Ahmed et al.
EXPERT REVIEW OF CLINICAL PHARMACOLOGY (2019)
Antibody-Based Therapies for Cutaneous T-Cell Lymphoma
Macartney Welborn et al.
AMERICAN JOURNAL OF CLINICAL DERMATOLOGY (2019)
The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas
Rein Willemze et al.
BLOOD (2019)
Antibody-drug conjugates (ADCs) for cancer therapy: Strategies, challenges, and successes
Meghdad Abdollahpour-Alitappeh et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2019)
Secreted Gal-3BP is a novel promising target for non-internalizing Antibody-Drug Conjugates
Francesco Giansanti et al.
JOURNAL OF CONTROLLED RELEASE (2019)
Cleavable linkers in antibody-drug conjugates
Jonathan D. Bargh et al.
CHEMICAL SOCIETY REVIEWS (2019)
Pharmacologic Considerations in the Disposition of Antibodies and Antibody-Drug Conjugates in Preclinical Models and in Patients
Andrew T. Lucas et al.
ANTIBODIES (2019)
Antibody structure and engineering considerations for the design and function of Antibody Drug Conjugates (ADCs)
Ricarda M. Hoffmann et al.
ONCOIMMUNOLOGY (2018)
Elimination of melanoma by sortase A-generated TCR-like antibody-drug conjugates (TL-ADCs) targeting intracellular melanoma antigen MART-1
Jun Lai et al.
BIOMATERIALS (2018)
Merkel cell carcinoma and cellular cytotoxicity: sensitivity to cellular lysis and screening for potential target antigens suitable for antibody-dependent cellular cytotoxicity
Jocelyn Ollier et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2018)
LRRC15 Is a Novel Mesenchymal Protein and Stromal Target for Antibody-Drug Conjugates
James W. Purcell et al.
CANCER RESEARCH (2018)
Preclinical Antitumor Activity of a Novel Anti-c-KIT Antibody-Drug Conjugate against Mutant and Wild-type c-KIT-Positive Solid Tumors
Tinya Abrams et al.
CLINICAL CANCER RESEARCH (2018)
EV20-mediated delivery of cytotoxic auristatin MMAF exhibits potent therapeutic efficacy in cutaneous melanoma
Emily Capone et al.
JOURNAL OF CONTROLLED RELEASE (2018)
Cooperative targeting of melanoma heterogeneity with an AXL antibody-drug conjugate and BRAF/MEK inhibitors
Julia Boshuizen et al.
NATURE MEDICINE (2018)
Glycoprotein Non-Metastatic Melanoma Protein B (GPNMB) and Cancer: A Novel Potential Therapeutic Target
Manisha Taya et al.
STEROIDS (2018)
Immunomodulatory effects of BRAF and MEK inhibitors: Implications for Melanoma therapy
Marvin Kuske et al.
PHARMACOLOGICAL RESEARCH (2018)
Rovalpituzumab Tesirine: A Novel DLL3-Targeting Antibody-Drug Conjugate
Bilal H. Lashari et al.
DRUGS IN R&D (2018)
Cemiplimab: First Global Approval
Anthony Markham et al.
DRUGS (2018)
Mechanisms of resistance to BRAF and MEK inhibitors and clinical update of US Food and Drug Administration-approved targeted therapy in advanced melanoma
Sunilkumar Kakadia et al.
ONCOTARGETS AND THERAPY (2018)
Improving Immunotherapy Through Glycodesign
Matthew J. Buettner et al.
FRONTIERS IN IMMUNOLOGY (2018)
Primary and Acquired Resistance to Immune Checkpoint Inhibitors in Metastatic Melanoma
Tuba N. Gide et al.
CLINICAL CANCER RESEARCH (2018)
Non-internalizing antibody-drug conjugates display potent anti-cancer activity upon proteolytic release of monomethyl auristatin E in the subendothelial extracellular matrix
Remy Gebleux et al.
INTERNATIONAL JOURNAL OF CANCER (2017)
Optimization of a PEGylated Glucuronide-Monomethylauristatin E Linker for Antibody-Drug Conjugates
Patrick J. Burke et al.
MOLECULAR CANCER THERAPEUTICS (2017)
Diagnostic, prognostic and therapeutic role of CD30 in lymphoma
John Matthew R. Pierce et al.
EXPERT REVIEW OF HEMATOLOGY (2017)
Strategies and challenges for the next generation of antibody drug conjugates
Alain Beck et al.
NATURE REVIEWS DRUG DISCOVERY (2017)
Targeting GPNMB with glembatumumab vedotin: Current developments and future opportunities for the treatment of cancer
April A. N. Rose et al.
PHARMACOLOGY & THERAPEUTICS (2017)
Merkel cell carcinoma
Juergen C. Becker et al.
NATURE REVIEWS DISEASE PRIMERS (2017)
Phase 1/2 Study of the CD56-Targeting Antibody-Drug Conjugate Lorvotuzumab Mertansine (IMGN901) in Combination With Carboplatin/Etoposide in Small-Cell Lung Cancer Patients With Extensive-Stage Disease
Mark A. Socinski et al.
CLINICAL LUNG CANCER (2017)
Antibody drug conjugates and bystander killing: is antigen-dependent internalisation required?
Alexander H. Staudacher et al.
BRITISH JOURNAL OF CANCER (2017)
Cutaneous Squamous Cell Carcinoma: Review of the Eighth Edition of the American Joint Committee on Cancer Staging Guidelines, Prognostic Factors, and Histopathologic Variants
Kiran Motaparthi et al.
ADVANCES IN ANATOMIC PATHOLOGY (2017)
HER3/ErbB3, an emerging cancer therapeutic target
Ningyan Zhang et al.
ACTA BIOCHIMICA ET BIOPHYSICA SINICA (2016)
MAPK Pathway Inhibitors Sensitize BRAF-Mutant Melanoma to an Antibody-Drug Conjugate Targeting GPNMB
April A. N. Rose et al.
CLINICAL CANCER RESEARCH (2016)
Phase I study of IMGN901, a CD56-targeting antibody-drug conjugate, in patients with CD56-positive solid tumors
Manisha H. Shah et al.
INVESTIGATIONAL NEW DRUGS (2016)
Antibody-drug conjugates for cancer therapy
Anish Thomas et al.
LANCET ONCOLOGY (2016)
Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates
Heather Donaghy
MABS (2016)
PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma
Paul T. Nghiem et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
New uses for brentuximab vedotin and novel antibody drug conjugates in lymphoma
Michele Merli et al.
EXPERT REVIEW OF HEMATOLOGY (2016)
Antibody-Drug Conjugates for Cancer Therapy
Adam C. Parslow et al.
BIOMEDICINES (2016)
Chemoenzymatic Conjugation of Toxic Payloads to the Globally Conserved N-Glycan of Native mAbs Provides Homogeneous and Highly Efficacious Antibody-Drug Conjugates
Remon van Geel et al.
BIOCONJUGATE CHEMISTRY (2015)
Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and Sezary Syndrome With Variable CD30 Expression Level: A Multi-Institution Collaborative Project
Youn H. Kim et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Cutaneous Lymphoma International Consortium Study of Outcome in Advanced Stages of Mycosis Fungoides and Sezary Syndrome: Effect of Specific Prognostic Markers on Survival and Development of a Prognostic Model
Julia J. Scarisbrick et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
CD30 Downregulation, MMAE Resistance, and MDR1 Upregulation Are All Associated with Resistance to Brentuximab Vedotin
Robert Chen et al.
MOLECULAR CANCER THERAPEUTICS (2015)
Evolving Strategies for Target Selection for Antibody-Drug Conjugates
Marc Damelin et al.
PHARMACEUTICAL RESEARCH (2015)
Brentuximab as a Treatment for CD30+ Mycosis Fungoides and Sezary Syndrome
Tarun Mehra et al.
JAMA DERMATOLOGY (2015)
Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma
Yu-Tzu Tai et al.
BLOOD (2014)
An Antibody-Drug Conjugate That Targets Tissue Factor Exhibits Potent Therapeutic Activity against a Broad Range of Solid Tumors
Esther C. W. Breij et al.
CANCER RESEARCH (2014)
Curative Properties of Noninternalizing Antibody-Drug Conjugates Based on Maytansinoids
Elena Perrino et al.
CANCER RESEARCH (2014)
Phase I/II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Patients With Advanced Melanoma
Patrick A. Ott et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
MAPK Pathway Inhibition Enhances the Efficacy of an Anti-Endothelin B Receptor Drug Conjugate by Inducing Target Expression in Melanoma
Jyoti Asundi et al.
MOLECULAR CANCER THERAPEUTICS (2014)
The effect of the neonatal Fc receptor on human IgG biodistribution in mice
Nancy Chen et al.
MABS (2014)
The receptor tyrosine kinase Axl regulates cell-cell adhesion and stemness in cutaneous squamous cell carcinoma
M. A. Cichon et al.
ONCOGENE (2014)
Antibody-Drug Conjugates in Cancer Therapy
Eric L. Sievers et al.
ANNUAL REVIEW OF MEDICINE, VOL 64 (2013)
An Epithelial-Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl as a Therapeutic Target for Overcoming EGFR Inhibitor Resistance
Lauren Averett Byers et al.
CLINICAL CANCER RESEARCH (2013)
Melanoma adapts to RAF/MEK inhibitors through FOXD3-mediated upregulation of ERBB3
Ethan V. Abel et al.
JOURNAL OF CLINICAL INVESTIGATION (2013)
Safety and Clinical Activity of a Combination Therapy Comprising Two Antibody-Based Targeting Agents for the Treatment of Non-Hodgkin Lymphoma: Results of a Phase I/II Study Evaluating the Immunoconjugate Inotuzumab Ozogamicin With Rituximab
Luis Fayad et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
HER3 Overexpression and Survival in Solid Tumors: A Meta-analysis
Alberto Ocana et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2013)
Tumor-Specific Activation of an EGFR-Targeting Probody Enhances Therapeutic Index
Luc R. Desnoyers et al.
SCIENCE TRANSLATIONAL MEDICINE (2013)
The roles of TGFβ in the tumour microenvironment
Michael Pickup et al.
NATURE REVIEWS CANCER (2013)
The relationship between tissue factor and cancer progression: insights from bench and bedside
Yascha W. van den Berg et al.
BLOOD (2012)
The Melanosomal Protein PMEL17 as a Target for Antibody Drug Conjugate Therapy in Melanoma
Youjun Chen et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2012)
Safety and efficacy of brentuximab vedotin in patients with Hodgkin lymphoma or systemic anaplastic large cell lymphoma
Christos Vaklavas et al.
THERAPEUTIC ADVANCES IN HEMATOLOGY (2012)
An Antibody-Drug Conjugate Targeting the Endothelin B Receptor for the Treatment of Melanoma
Jyoti Asundi et al.
CLINICAL CANCER RESEARCH (2011)
Antibody Conjugate Therapeutics: Challenges and Potential
Beverly A. Teicher et al.
CLINICAL CANCER RESEARCH (2011)
GPNMB expression in uveal melanoma: a potential for targeted therapy
Michelle D. Williams et al.
MELANOMA RESEARCH (2010)
Roles of endothelin signaling in melanocyte development and melanoma
Amy Saldana-Caboverde et al.
PIGMENT CELL & MELANOMA RESEARCH (2010)
Resistance to Tyrosine Kinase Inhibitors in Gastrointestinal Stromal Tumors
Ann W. Gramza et al.
CLINICAL CANCER RESEARCH (2009)
Role of Tissue Factor in Cancer
Raj S. Kasthuri et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index
Jagath R. Junutula et al.
NATURE BIOTECHNOLOGY (2008)
Phase I trial with the CD44v6-targeting immunoconjugate bivatuzumab mertansine in head and neck squamous cell carcinoma
Herbert Riechelmann et al.
ORAL ONCOLOGY (2008)
Clonal integration of a polyomavirus in human Merkel cell carcinoma
Huichen Feng et al.
SCIENCE (2008)
Paul Ehrlich's magic bullet concept: 100 years of progress
Klaus Strebhardt et al.
NATURE REVIEWS CANCER (2008)
Fc gamma receptors as regulators of immune responses
Falk Nimmerjahn et al.
NATURE REVIEWS IMMUNOLOGY (2008)
TGFβ:: the molecular Jekyll and Hyde of cancer
Brian Bierie et al.
NATURE REVIEWS CANCER (2006)
Potent cytotoxicity of an auristatin-containing antibody-drug conjugate targeting melanoma cells expressing melanotransferrin/p97
Leia M. Smith et al.
MOLECULAR CANCER THERAPEUTICS (2006)
CR011, a fully human monoclonal anti body-auristatin E conjugate, for the treatment of melanoma
KF Tse et al.
CLINICAL CANCER RESEARCH (2006)
Antibody targeted drugs as cancer therapeutics
D Schrama et al.
NATURE REVIEWS DRUG DISCOVERY (2006)
KIT (CD117): A review on expression in normal and neoplastic tissues, and mutations and their clinicopathologic correlation
M Miettinen et al.
APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY (2005)
Arming antibodies: prospects and challenges for immunoconjugates
AM Wu et al.
NATURE BIOTECHNOLOGY (2005)
Endothelin B receptor blockade inhibits dynamics of cell interactions and communications in melanoma cell progression
A Bagnato et al.
CANCER RESEARCH (2004)
Phase I clinical trial of the immunocytokine EMD 273063 in melanoma patients
DM King et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Antibody-targeted radiation cancer therapy
DE Milenic et al.
NATURE REVIEWS DRUG DISCOVERY (2004)
Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate
KJ Hamblett et al.
CLINICAL CANCER RESEARCH (2004)
The endothelin axis: Emerging role in cancer
J Nelson et al.
NATURE REVIEWS CANCER (2003)
Expression of the 90K tumor-associated protein in benign and malignant melanocytic lesions
AM Cesinaro et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2002)
分享论文
